利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

360 条记录 (耗时 0.041 秒)

    MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS
    94.
    发明申请
    MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS 审中-公开

    公开(公告)号：US20170296559A1

    公开(公告)日：2017-10-19

    申请号：US15369164

    申请日：2016-12-05

    申请人： Therapeutic Research LLC

    发明人： Jay Pravda

    IPC分类号： A61K31/606 ,  A61K31/385 ,  A61K31/198 ,  A61K9/00 ,  A61K31/19 ,  A61K31/58 ,  A61K31/366

    CPC分类号： A61K31/58 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/10 ,  A61K9/48 ,  A61K31/19 ,  A61K31/198 ,  A61K31/352 ,  A61K31/366 ,  A61K31/381 ,  A61K31/385 ,  A61K31/606 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

    摘要： The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. The subject invention also concerns methods for screening for, assessing risk of developing, and/or diagnosing conditions associated with oxidative stress, such as ulcerative colitis and other inflammatory bowel disorders.

    DELAYED RELEASE DRUG FORMULATION
    96.
    发明申请
    DELAYED RELEASE DRUG FORMULATION 审中-公开

    公开(公告)号：US20170266117A1

    公开(公告)日：2017-09-21

    申请号：US15612065

    申请日：2017-06-02

    申请人： Tillotts Pharma AG

    发明人： Felipe Josè OLIVEIRA VARUM ,  Roberto Carlos BRAVO GONZÁLEZ ,  Thomas BUSER ,  Abdul Waseh BASIT ,  Ana Cristina FREIRE

    IPC分类号： A61K9/28 ,  A61K31/196 ,  A61K31/606 ,  A61K31/616 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  A61K9/00 ,  A61K9/20

    摘要： In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

    Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
    97.
    发明授权
    Materials and methods for treatment and diagnosis of disorders associated with oxidative stress 有权
    用于治疗和诊断与氧化应激相关的疾病的材料和方法

    公开(公告)号：US09511049B2

    公开(公告)日：2016-12-06

    申请号：US14580212

    申请日：2014-12-22

    申请人： Jay Pravda

    发明人： Jay Pravda

    IPC分类号： A61K31/385 ,  A61K9/00 ,  A61K31/352 ,  A61K31/19 ,  A61K31/606 ,  A61K31/58 ,  A61K31/616 ,  A61K45/06 ,  A61K9/10 ,  A61K9/48

    CPC分类号： A61K31/58 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/10 ,  A61K9/48 ,  A61K31/19 ,  A61K31/198 ,  A61K31/352 ,  A61K31/366 ,  A61K31/381 ,  A61K31/385 ,  A61K31/606 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

    摘要： The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. The subject invention also concerns methods for screening for, assessing risk of developing, and/or diagnosing conditions associated with oxidative stress, such as ulcerative colitis and other inflammatory bowel disorders.

    摘要翻译： 本发明涉及用于预防和治疗与氧化应激相关的疾病状况或受损的还原环境（包括诸如克罗恩病和溃疡性结肠炎等炎症性肠病）的材料和方法。 本发明的另一方面涉及配制用作灌肠剂的组合物。 在一个实施方案中，适合作为灌肠施用的组合物包含有效量的5-ASA和类固醇，例如布地奈德或氢化可的松。 本发明还涉及配制用于口服给药的组合物。 在一个实施方案中，组合物包含α-硫辛酸和/或N-乙酰基-L-半胱氨酸（N-A-C）和/或L-谷氨酰胺。 α-硫辛酸可以是外消旋α-硫辛酸，R-硫辛酸或R-二氢硫辛酸。 本发明的方法包括施用本发明的化合物或组合物。 在一个实施方案中，将本发明的化合物或组合物直接滴注到患者体内。 在另一个实施方案中，口服给药化合物或组合物。 本发明还涉及用于筛选，评估发展和/或诊断与氧化应激相关的病症如溃疡性结肠炎和其它炎症性肠病的风险的方法。

    ENTERIC COATED TABLET
    99.
    发明申请
    ENTERIC COATED TABLET 审中-公开
    ENTERIC涂层片

    公开(公告)号：US20150374632A1

    公开(公告)日：2015-12-31

    申请号：US14769660

    申请日：2014-02-21

    申请人： ZERIA PHARMACEUTICAL CO., LTD.

    发明人： Akio RYU ,  Miyako OSADA

    IPC分类号： A61K9/28 ,  A61K31/606

    CPC分类号： A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/606

    摘要： To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.

    摘要翻译： 提供含有大量药用成分并具有足够抗冲击性的肠溶衣片剂，而不形成厚的肠溶衣层。 肠溶片剂含有（A）含有药物成分并具有1,000mg以上重量的核心片剂; （B）涂布在芯片表面上的水溶性聚合物的涂层; 和（C）溶解在pH7以上的肠溶衣层，其被涂布在含有水溶性聚合物的被覆层的表面上，其中，涂布层（B）的聚合物量与聚合物的量 涂层（C）的涂布层（C）为10〜18mg / cm 2，涂层（B）的聚合物量为6〜12mg / cm 2，涂层（C）的聚合物量为3〜6mg / cm 2 。